{
    "clinical_study": {
        "@rank": "137757", 
        "arm_group": [
            {
                "arm_group_label": "Tacrolimus dose regulation", 
                "arm_group_type": "Experimental", 
                "description": "Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "immunosuppressive therapy is managed either by standard practice at our center (Control)"
            }
        ], 
        "brief_summary": {
            "textblock": "ImmuKnow detects cell-mediated immunity in solid-organ transplant recipients undergoing\n      immunosuppressive therapy.  Increasing ImmuKnow values indicate a decrease of\n      immunosuppression and decreasing ImmuKnow values suggest an increase of immunosuppression.\n      The test measures the amount of ATP produced in CD4+ lymphocytes as a biomarker of\n      lymphocyte activation.  This study uses the ImmuKnow assay to proactively adjust\n      immunosuppressive therapy in adult liver transplant recipients to reduce the risk of adverse\n      events"
        }, 
        "brief_title": "Randomized Controlled Trial of ImmuKnow in Liver Transplantation", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Liver Disease", 
        "condition_browse": {
            "mesh_term": "Liver Diseases"
        }, 
        "detailed_description": {
            "textblock": "We performed a randomized prospective interventional trial where the Interventional group\n      had immunosuppression modified according to ImmuKnow values. Immunosuppression was decreased\n      by 25% if ImmuKnow values were less than 130 ng/mL ATP.  Similarly, immunosuppression was\n      increased by 25% if ImmuKnow values were greater than 450 ng/mL ATP.  Immunosuppression of\n      the Control group was managed by the Standard of Care at our institution.  ImmuKnow was\n      performed before liver transplant, after surgery and at each clinic visit with the\n      approximate schedule:  day 1; weekly, weeks 1-4; week 6; week 8; monthly, months 3-6; and\n      months 9 and 12.  ImmuKnow testing was repeated within 7 days of a suspected/confirmed\n      rejection or infection and again within 1 week of resolution."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  consecutive adult liver transplant recipients at our center;\n\n          -  patients not entered into other studies;\n\n          -  provided consent.\n\n        Exclusion Criteria:\n\n          -  available follow-up;\n\n          -  consent removed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "206", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764581", 
            "org_study_id": "BolognaCylex01"
        }, 
        "intervention": {
            "arm_group_label": "Tacrolimus dose regulation", 
            "description": "Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.  Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of  280 ng/mL corresponding with the greatest negative predictive value for either event", 
            "intervention_name": "Tacrolimus regulation according to ImmuKnow values", 
            "intervention_type": "Procedure", 
            "other_name": "Prograf"
        }, 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "immune monitoring", 
            "immune cell function ImmuKnow", 
            "randomized controlled trial", 
            "immunosuppression management", 
            "infection", 
            "rejection", 
            "liver transplantation", 
            "Cylex"
        ], 
        "lastchanged_date": "January 7, 2013", 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Interventional Trial of Immunosuppression Modification Based on the Cylex\u2122 ImmuKnow\u00ae Assay in Adult Liver Transplant Recipients", 
        "overall_official": {
            "affiliation": "Department of General Surgery and Transplantation; S.Orsola-Malpighi Hospital, University of Bologna", 
            "last_name": "Antonio Daniele Pinna, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Comparison of adverse events consisting of allograft rejection, severe infections, graft loss and death between the Control and Interventional groups", 
            "measure": "Comparison of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 months posttransplant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764581"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Bologna", 
            "investigator_full_name": "Matteo Ravaioli", 
            "investigator_title": "PhD, MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Bologna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Bologna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2010"
    }
}